Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. by Yano, Junko et al.
Masthead Logo
Thomas Jefferson University
Jefferson Digital Commons
Department of Obstetrics and Gynecology Faculty
Papers Department of Obstetrics and Gynecology
3-29-2019
Current patient perspectives of vulvovaginal
candidiasis: incidence, symptoms, management
and post-treatment outcomes.
Junko Yano
Louisiana State University Health Sciences Center
Jack D. Sobel
Wayne State University
Paul Nyirjesy
Drexel University
Ryan Sobel
Thomas Jefferson University, ryan.sobel@jefferson.edu
Valerie L. Williams
Louisiana State University Health Sciences Center
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/obgynfp
Part of the Obstetrics and Gynecology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Obstetrics and Gynecology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information,
please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Yano, Junko; Sobel, Jack D.; Nyirjesy, Paul; Sobel, Ryan; Williams, Valerie L.; Yu, Qingzhao; Noverr,
Mairi C.; and Fidel, Paul L., "Current patient perspectives of vulvovaginal candidiasis: incidence,
symptoms, management and post-treatment outcomes." (2019). Department of Obstetrics and
Gynecology Faculty Papers. Paper 52.
https://jdc.jefferson.edu/obgynfp/52
Authors
Junko Yano, Jack D. Sobel, Paul Nyirjesy, Ryan Sobel, Valerie L. Williams, Qingzhao Yu, Mairi C. Noverr, and
Paul L. Fidel
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/obgynfp/52
RESEARCH ARTICLE Open Access
Current patient perspectives of
vulvovaginal candidiasis: incidence,
symptoms, management and post-
treatment outcomes
Junko Yano1, Jack D. Sobel4, Paul Nyirjesy5, Ryan Sobel6, Valerie L. Williams3, Qingzhao Yu2, Mairi C. Noverr1,7 and
Paul L. Fidel Jr1*
Abstract
Background: Vulvovaginal candidiasis (VVC) is a common infection affecting women worldwide. Reports of
patterns/risk factors/trends for episodic/recurrent VVC (RVVC) are largely outdated. The purpose of this study was to
obtain current patient perspectives of several aspects of VVC/RVVC.
Methods: Business cards containing on-line survey information were distributed to healthy volunteers and patients
seeking standard, elective, or referral gynecologic care in university-affiliated Obstetrics/Gynecology clinics. The
internet-based questionnaire was completed by 284 non-pregnant women (78% Caucasian, 14% African American,
8% Asian).
Results: The majority of the participants (78%) indicated a history of VVC with 34% defined as having RVVC. The
most common signs/symptoms experienced were itching, burning and redness with similar ranking of symptoms
among VVC and RVVC patients. Among risk factors, antibiotic use ranked highest followed by intercourse, humid
weather and use of feminine hygiene products. A high number of respondents noted ‘no known cause’ (idiopathic
episodes) that was surprisingly similar among women with a history of either VVC or RVVC. VVC/RVVC episodes
reported were primarily physician-diagnosed (73%) with the remainder mostly reporting self-diagnosis and treating
with over-the-counter (OTC) medications. Most physician-diagnosed attacks utilized a combination of pelvic
examination and laboratory tests followed by prescribed antifungals. Physician-treated cases achieved a higher level
of symptom relief (84%) compared to those who self-medicated (57%). The majority of women with RVVC (71%)
required continual or long-term antifungal medication as maintenance therapy to control symptoms.
Conclusions: Current patient perspectives closely reflect historically documented estimates of VVC/RVVC prevalence
and trends regarding symptomatology, disease management and post-treatment outcomes.
Keywords: Vaginitis, Vulvovaginal candidiasis, VVC, RVVC, Epidemiology, Incidence rates, Candida albicans,
Symptomatology, Risk factors, Disease management
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Background
Vulvovaginal candidiasis (VVC) is a common fungal
infection caused by Candida species, predominantly C.
albicans [1]. Historical reports approximate that 70% of
all women will have at least one episode of VVC during
their reproductive years [2]. The pathological hallmark
of the disease is an acute inflammatory condition of the
vulva and vaginal mucosa induced by and accompanied
with overgrowth of Candida organisms that normally
exists as a quiescent vaginal commensal [3]. Signs/symp-
toms of VVC are typically characterized by white clumpy
discharge, burning, redness and itching in the vulva and
vagina, and dyspareunia [4]. The onset of most VVC
cases is believed to be associated with a wide range of
predisposing factors or triggering events including the
use of antibiotics, increased estrogen levels (e.g. high
estrogen oral contraceptives, hormone replacement ther-
apies, pregnancy), uncontrolled diabetes mellitus, sexual
activities and tight-fit clothing [2, 5]. In addition, an esti-
mated 8 to 10% of women are susceptible to recurrent
VVC (RVVC), having 4 or more episodes per annum [4].
Multiple recurring infections are often idiopathic with-
out regard to the array of potential risk factors. Unlike
most episodic or sporadic VVC, RVVC cases require
maintenance regimens with long-term use of antifungals
over several months or longer to avoid recurrence [4, 6].
Despite the high incidence rates worldwide, epidemio-
logical data supporting the current estimates of VVC or
RVVC prevalence rates had been limited, largely histor-
ical, and often anecdotal. More recently, however, several
global studies have been reported. One reports the
worldwide prevalence of RVVC at approximately 138
million women annually, and an additional 372 million
over one’s lifetime, causing substantial morbidity and
economic burden [7]. Another large-scale multi-country
internet panel survey indicated a lifetime RVVC preva-
lence rate of 9% by age 50 with the vast majority of
episodes occurring between 19 to 35 years of age [8],
which was remarkably similar to the historical estimates
[9]. Despite these global studies on incidence/prevalence
rates worldwide, current information/perspectives on
VVC/RVVC disease trends is still needed and critical for
reporting on aspects of vaginal infections, including
diagnostics and therapeutic approaches, understanding
host immunity and pathogenesis, and behavioral factors
associated with disease etiology. Indeed, a large body of
current literature on host defense mechanisms against
VVC/RVVC and associated immunopathology [10–14]
has relied on long past historical epidemiological cita-
tions for VVC/RVVC that may not accurately reflect
current disease-associated trends.
The objective of this study was to conduct a contem-
porary survey of women with a history of VVC and
RVVC among general populations and those seeking
standard or elective care at several university-affiliated
Obstetrics and Gynecology clinics or referral clinics, to
determine current trends including diagnostic/manage-
ment parameters, ranking of disease symptomatology,
and post-treatment outcomes, in addition to prevalence
rates.
Methods
Study designs
The survey included responses by 284 non-pregnant
women over a period of February 2016 to May 2018.
Business cards containing on-line survey information
were distributed to subjects who sought gynecologic care
in university-affiliated Obstetrics and Gynecology clinics
at the time of visit with a health care provider or via
group encounters (meetings, classes, community activ-
ities). The university-affiliated Ob/Gyn clinics included
the following: Detroit Medical Center, Drexel University,
Louisiana State University Health Sciences Center
(LSUHSC) – New Orleans and Thomas Jefferson Uni-
versity. Eligible subjects (any adult women) participated
in the survey on a voluntary basis by accessing a speci-
fied URL via internet and answering a questionnaire
using Survey Monkey (http://www.surveymonkey.com).
Access to the survey web site was open to the general
public without password restriction. The questionnaire
was approved by the Institutional Review Board at
LSUHSC, New Orleans with a waiver of informed
consent. The survey was administered anonymously and
included no identifiers linking data to individual
respondents.
Survey contents and interpretations
The survey questionnaire included a total of 13 ques-
tions regarding i) participant demographics, ii) previous
history of VVC, iii) lifetime/annual frequencies of VVC
episodes, iv) vulvovaginal signs and symptoms, v) known
causes if any, vi) choice of clinical interventions for diag-
noses and treatment regimens, and vii) post-treatment
outcomes (Table 1). The questions included 2 to 12
answer choices per question. The participants were
presented with the questions one at a time on their de-
vice of choice and given the option of ‘no response’. The
exception was the first question in which participants
answering ‘no history’ were led out of the remainder of
the survey. For those questions with more than two
answer choices, the responses were combined into two
categories for analyses. Not applicable (N/A) answers
were interpreted as missing values (Additional file 1).
Statistical analyses
Fisher’s exact test was used for a binomial proportion
comparing two populations of women choosing one of
two responses (i.e. “yes” versus “no”) of the question. For
Yano et al. BMC Women's Health           (2019) 19:48 Page 2 of 9
questions with multiple answer choices, the entire popu-
lation of the respondents were categorized into two
groups based on criteria specified for each survey
data set and analyzed for binomial distributions. For
proportions of RVVC patient age ranges, Pearson’s
Chi-squared tests were used to analyze for equal
distributions in each age group. All statistical analyses
were performed using the SAS version 9.4 software
(SAS Institute, Cary, NC).
Results
Demographic characteristics of the participants
Race and age group distributions of the survey partici-
pants were assessed prior to collecting clinical informa-
tion in regards to VVC/RVVC. Racial data on
respondents who completed the survey included Cauca-
sian (n = 202, 77.7%), African American (n = 37, 14.2%)
and Asian (n = 21, 8.1%) women (Table 2). No partici-
pants of native American or native Hawaiian/Pacific
Islander origins were reported. A small proportion of
women identified themselves as Hispanic or Latino
(n = 20, 8.2%). Approximately one half of the participants
were within reproductive age (18–25 years of age, n = 36,
13.6%; 26–40 years of age, n = 131, 49.4%), and the rest
were within perimenopausal or postmenopausal age (41–
55 years of age, n = 59, 22.3%; 56 or older, n = 39, 14.7%).
Prevalence of VVC/RVVC
Prevalence was determined based on the number of in-
dividual VVC/RVVC episodes in a respondent’s lifetime
and, if any, annually as well. A significantly large propor-
tion of the respondents (n = 220, 77.5%, p < 0.0001)
reported at least one episode of VVC in their lifetime
(Table 2, Fig. 1a). Among those with previous episode(s)
of infection, a lower number of respondents reported
having > 10 lifetime episodes (n = 89, 43.6%) compared
to those that reported fewer than 10 lifetime episodes
(n = 115, 56.4%, p < 0.05) (Fig. 1a). Likewise, when evalu-
ated based on the number of VVC episodes per year, the
distribution of women with > 3 episodes (i.e. RVVC)
Table 1 List of questions and responses in the survey
questionnaire
Questions Response choices
Demographics Race
Ethnicity
Age
Previous history
of VVC/RVVC
Yes
No
Frequency
(lifetime)
1–10 episodes
> 10 episodes
Frequency
(annual)
0–3 episodes
> 3 episodes
Signs/symptomsa Itching, burning, cottage cheese-like discharge,
redness in the vaginal area, vaginal pain,
vaginal dryness, vaginal pain, pain during intercourse
Causesa No known cause, oral contraceptives, antibiotics,
hormone replacement therapy, diabetes, humid
weather, pregnancy, after intercourse, after oral
sex, a new sexual partner, feminine hygiene
products, other
Diagnosis Physician-diagnosed with exam and lab test, treated
with prescription oral or topical medication.
Physician-diagnosed with exam and lab test, treated
with OTC topical medication.
Physician-diagnosed with exam only, treated with
prescription oral or topical medication.
Physician-diagnosed with exam only, treated with
OTC topical medication.
Self-diagnosed and treated with OTC topical
medication.
Other.
Relief Physician-treated, relief
Self-treated, relief
Physician-treated, no relief
Self-treated, no relief
Post-treatment
outcome
Cured
Recurred/relapse
RVVC
management
Constant antifungal medication, relief
Constant antifungal medication, no relief
As needed antifungal medication, relief
Avoiding known risk factors without medication
aRespondents indicated all applicable choices
Table 2 Demographics of study participants with a history of
VVC/RVVC
Race Caucasian 77.7% (202)b
African American 14.2% (37)
Asian 8.1% (21)
Native American 0.0% (0)
Native Hawaiian/Pacific
Islander
0.0% (0)
Ethnic category Hispanic or Latino 8.2% (20)
Not Hispanic or Latino 91.8% (224)
Age 18–25 13.6% (36)
26–40 49.4% (131)
41–55 22.3% (59)
> 55 14.7% (39)
Lifetime history
of infection
No history 22.5% (64)
≥1 77.5% (220)
Annual frequency
of infection
≤3 65.4% (132)
> 3 (RVVC)a 34.6% (70)
aRVVC, recurrent vulvovaginal candidiasis defined as 4 or more acute episodes
in a 12-month period
bValues in parentheses indicate the number of respondents who selected each
response choice
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(n = 70 women, 34.7%,) were significantly lower com-
pared to those with ≤3 annual episodes (n = 132, 65.3%,
p < 0.0001) (Table 2, Fig. 1b). Subsequently, the RVVC
population of the respondents were further stratified
into specific age groups. The proportion of RVVC
women in the range of 26 to 40 years of age was signifi-
cantly higher than other age groups ranging 18 to 25
years, 41 to 55 years or, > 55 years (p < 0.001) (Fig. 1b).
Clinical features of VVC/RVVC
Information regarding vaginal signs and symptoms experi-
enced during VVC episodes was reported by both women
with infrequent history of infection as well as those with a
history of recurrence. Overall, the most common clinical
characteristics were associated with vaginal inflammation,
namely itching (91.2% of all respondents; VVC-92.4%;
RVVC-90.0%) followed by burning (68.3% of all respon-
dents; VVC-62.1%; RVVC-81.4%) (Table 3). Additional
common features of symptomatic VVC/RVVC episodes
included redness (58.1%), vaginal discharge described as
thick, white or cottage cheese-like (55.6%), pain during
intercourse (40.5%), vaginal pain (38.1%) and vaginal
dryness (29.3%). Greater than 50% of the respondents
(55.4%) reported that their VVC episodes had no
known cause. These idiopathic attacks were reported by
similar proportions of women with a history of VVC
(51.2%) and RVVC (62.9%). If a cause was reported,
antibiotic use was the most common risk factor (37.8%)
followed by intercourse (21.6%), hormone-induced
conditions (pregnancy, use of oral contraceptives, hor-
mone replacement therapy, 13.7%) and humid weather
(11.3%). There was moderate association of VVC/
RVVC incidence with use of feminine hygiene products
(10.8%), having a new sexual partner (8.3%) or receptive
oral sex (6.9%). A small number of cases (< 3.0%) were
reported as diabetes-related.
no history
22.5%
1 episodes
77.5%
1-3 episodes
29.0%
4-10 episodes
28.4%
>10 episodes
43.6%
(p<0.0001)
(p<0.05)
Lifetime
Annual
monthly
18.3%
>3 
episodes
16.3%
2-3 
episodes
14.4%
1 episode
27.2%
0 
episodes
23.8%
(p<0.0001)
Age 18-25
18.6%
Age 26-40
44.3%
Age 41-55
24.3%
(p<0.001)
Age >55
12.9%
Among VVC/RVVC
Among RVVC
A
B
Fig. 1 Prevalence of VVC/RVVC and distribution of lifetime/annual frequencies of infection. a Lifetime history of VVC in participating women (n = 284,
pie chart) was assessed by a self-reported survey. Total VVC episodes in respondents with disease history were further stratified by lifetime frequencies
(n = 204, bar chart). b Respondents with previous VVC episodes were classified by annual frequencies (n = 202, pie chart), and those with annual
frequencies of > 3 VVC episodes were further stratified by age (n = 70, bar chart). The percentage in each section indicates the proportion of women
among those who reported answers to each parameter. Data were analyzed by Fisher’s exact test for binomial proportions comparing two
populations of women categorized by the dashed lines. NS, not significant
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Diagnosis and management of VVC/RVVC
VVC was either self-diagnosed based on vaginal symp-
toms alone followed by self-medication with over-the--
counter (OTC) antifungals, or diagnosed and treated by
a physician. Most respondents in this study had infec-
tions diagnosed by physicians (72.9%), with a smaller
proportion (27.1%) opting self-diagnosis without seeking
medical care (Fig. 2a) (p < 0.0001). Among women report-
ing physician-diagnosed VVC/RVVC, the clear majority of
cases (71.7%) were determined by the combination of
performing a pelvic examination for signs of vaginitis and
conducting laboratory tests involving wet mount micros-
copy, cultures, or nucleic acid amplification-based detec-
tion to confirm the presence of fungal organisms. Of note,
several women reported that physician diagnosis was
based upon a pelvic examination alone (28.3%). Following
physician diagnosis, most VVC cases involved treatment
with oral or topical antifungal medications prescribed by
the physician (66.5%) with a minor portion instructed by
physicians to treat with OTC medications (7.5%) (Fig. 2b).
Women who reported self-diagnosed VVC (24.1%) tended
to OTC antifungal medications for treatment or occasion-
ally experienced spontaneous clearance of symptoms
without treatment (1.9%).
Clinical outcomes following treatment
Clinical outcomes of women receiving treatment for
VVC/RVVC included a spectrum of symptom control or
relief to recurrence of symptoms (often rapid). A signifi-
cantly larger proportion of women who were treated by
physicians achieved relief of symptoms (84.4% vs. 15.6%
non-relief, p < 0.0001) (Table 4). Conversely, the relief
rate was considerably lower in women with a history of
self-diagnosis and self-directed therapy (57.4% vs. 42.6%
non-relief, p = 0.06). Among those who attained symp-
tom relief following treatment with an antifungal, pro-
portions of women who ultimately experienced a repeat
episode and those who reported no further episodes
were similar (53.2% recurrence vs. 46.8% cure, p = 0.20).
In the RVVC population, 71% achieved symptom relief
by utilizing maintenance antifungal therapy or on an
as-needed basis, whereas 19% failed to achieve relief of
symptoms despite multiple regimens of antifungal medi-
cation. A small proportion of RVVC women (9.6%)
reported that avoiding triggering factors or events that
they recognized as provoking a symptomatic episode
was effective management of RVVC.
Discussion
Despite decades of research and high global prevalence,
VVC and RVVC continue to present major health issues
in affected women [2, 7]. Until very recently, general
epidemiological information has been limited in contem-
porary literature and consequently, reports of current
research in a variety of areas related to VVC/RVVC have
referenced predominantly long past historical epidemio-
logical data/observations. Results from the current
survey provide a current patient perspective for several
aspects of VVC/RVVC that can be used to compare to
historical data and provide a contemporary resource for
citation.
Data collected from 284 women showed a high pro-
portion with a history of at least one previous episode of
VVC (78%), with the majority of women with 3 or less
annual episodes (65%) and a smaller proportion of those
with 4 or more annual episodes (35%, i.e., RVVC). If one
removes the RVVC sub-population, the lifetime preva-
lence is reduced to 68%. In either case, the reported
lifetime history of VVC in this population of women is
remarkably similar to historical reports (~ 75%) [15–18].
Although the proportion of the RVVC group in this
population was relatively high, owing to the inclusion of
many women seeking specialist gynecologic care, this
provided a large sample size of women with a history of
VVC/RVVC (n = 204) to provide their perspectives. The
race distribution (78% Caucasian, 14% African Ameri-
can, and 8% Asian) was reflective of the participant pool
and not designed for matching by age or race.
Table 3 Clinical features of VVC symptomatology and risk
factors associated with disease
Signs/symptoms Itching 91.2% (187)a
Burning 68.3% (140)
Redness in the vaginal area 58.1% (119)
Cottage cheese like discharge 55.6% (114)
Pain during sex 40.5% (83)
Vaginal pain 38.1% (78)
Vaginal dryness 29.3% (60)
Causes No known cause 55.4% (113)
Antibiotics 37.8% (77)
After intercourse 21.6% (44)
Humid weather 11.3% (23)
Use of feminine hygiene product
or douching
10.8% (22)
Having a new sexual partner 8.3% (17)
Pregnancy 7.8% (16)
After oral sex 6.9% (14)
Taking oral contraceptives 5.4% (11)
Diabetes 2.5% (5)
Hormone replacement therapy 0.5% (1)
Othersb 17.2% (35)
aValues in parentheses indicate the number of respondents who selected each
response choice
bIncluding high sugar diet, exercising, stress, before/after menstruation
and swimming
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The current survey estimates that approximately 38%
of VVC cases are associated with antibiotic use, similar
to previous estimates of 33% [9]. Interestingly, the high
rate of responses (55%) denoting ‘no known cause’ for
their episodes (idiopathic) was not dominated by RVVC
respondents who are characteristically in the idiopathic
category relative to cause [4]. Quite the contrary, there
was a similar percentage of women with VVC and RVVC
noting ‘no known cause’ (52 vs. 63%, respectively). This
suggests that while the cause of episodic VVC is often
known, there is an equally high proportion of acute VVC
cases that are idiopathic similar to RVVC.
As historically reported, signs/symptoms associated
with vulvovaginal inflammation (i.e. pruritus, burning,
redness) and vaginal discharge are the hallmark manifes-
tations of an acute VVC episode [19], which was also
clearly indicated in the current survey. Interestingly,
ranking of symptoms reported by those with episodic
VVC was comparable to those experienced during
RVVC when analyzed independently. Based on the suffi-
cient numbers of women with VVC and RVVC in the
survey, these data have significant power to suggest that
the clinical pathology of RVVC is quite similar, if not
identical, to acute VVC. It is noteworthy, however, that
the frequency of women reporting multiple symptoms
was higher in those with RVVC. This may be due simply
to the relative frequency of the infection and a higher
level of attentiveness to the accompanying signs/
symptoms.
Among the RVVC population, the highest proportion
were in the age ranging from 26 to 40. This is consistent
with historical data and likely reflects the reported hor-
monal and behavioral predisposing factors to infection
[20]. The relatively high proportions of RVVC rates in
the perimenopausal (41 to 55 years of age) and postmen-
opausal (56 or older) populations may reflect potential
age-related health conditions such as exogenous estro-
gen use to treat atrophy. Indeed, a study conducted in
Physician-
diagnosed
72.9%
Self-
diagnosed
27.1%
Exam only
28.3%
Exam and lab tests
71.7%
A
B
Rx medication 
by physician
66.5%OTC 
medication 
suggested by 
physician
7.5%
OTC 
self-medicated
24.1%
Untreated
1.9%
(p<0.0001)
Physician-diagnosed
Fig. 2 Methods of disease diagnoses and management in women seeking treatment for vaginitis. a The process of diagnosing vaginitis
conditions by participating women (n = 214, pie chart) was assessed by a self-reporting survey. Methods of physician-based diagnoses used in
respondents seeking medical care were further classified (n = 152, bar chart). b The respondents who underwent antifungal treatment (n = 212)
were categorized based on diagnostic and therapeutic approaches. The percentage in each section indicates the proportion of women among
those who reported answers to each parameter. Data (A, pie chart) were analyzed by Fisher’s exact test for a binomial proportion comparing two
populations of women opting for physician-based diagnosis and self-diagnosis/other (dashed lines). OCT, over-the-counter (non-prescription)
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patients attending a vulvar disease referral clinic re-
ported that nearly 50% of women diagnosed with VVC/
RVVC were on hormone replacement therapy [21].
Regarding diagnosis and treatment, results showed
that a significantly greater proportion of respondents
had their episodes physician-diagnosed and treated with
prescription antifungal drugs, leading to control/relief of
symptoms in 84% of cases. These observations closely
parallel previously reported estimates of 80 to 90% cure
rates (defined by resolution of signs/symptoms and
negative mycological tests) by treatment with topical or
oral azoles [22, 23]. Also, consistent with a previous re-
port estimating that only 38% of cases can be diagnosed
correctly by symptomatology alone [19], our survey
showed poor relief rate (57%) among women who re-
ported they self-diagnosed and self-medicated with OTC
drugs. For RVVC, a previous study reported that relapse
occurred in 50% of women who failed to initiate a main-
tenance regimen [24]. This was reflective in the current
survey where > 71% of women with RVVC reported re-
quiring constant/as needed antifungal therapy to sustain
relief. The overall relapse rate noted by the respondents
(53%) is likely reflective of the relatively large RVVC
population surveyed.
We acknowledge several limitations to the current
study. It is important to note that the VVC diagnosis/
cure data described was solely based on self-reported
data as no formal chart screening was performed. As a
result, we acknowledge that the open survey format
leaves room for inaccuracies that should not be over-
looked. For example, poor relief rate among women
relying on self-diagnosis may have resulted from self-mis-
diagnosis. Indeed, signs and symptoms of RVVC are fre-
quently mistaken for many other conditions such as
bacterial vaginosis or persistent vulvar vestibulitis, and
inadequate diagnosis without clinical examinations often
leads to chronic vulvovaginal conditions [7, 25]. But
despite potential inaccuracies, these current data are re-
markably similar to historical information [19, 22, 23]. The
relatively small sample size (n = 284) represented another
limitation, especially considering the recent internet-based
multi-country survey on RVVC prevalence that included
6100 respondents [26]. However, most clinic-based VVC/
RVVC studies consist of sample sizes typical of the present
study [3, 27–32]. More importantly, however, is the recog-
nition of selection/accrual bias in the current dataset
owing to the fact that the participants were mainly com-
prised of women seeking care or continued care by a
gynecologist, and often those specializing in chronic/recur-
rent VVC. Indeed, > 34% of the respondents reported
RVVC. This introduced a significant bias in the participant
pool that likely resulted in overestimation of the number
of physician-diagnosed VVC/RVVC cases although the
overall lifetime VVC incidence rate (~ 78%) were compar-
able to historical estimates (~ 75%) [15–18]. It is assumed
that the proportion of self-diagnosed VVC/RVVC cases
would be higher in a more randomized population with all
respondents devoid of attending established clinics. We
recognize that these results may not be fully representative
of a broader general population and thus may be another
potential limitation. On the other hand, the inclusion of
women with higher than average incidence rates of RVVC
may actually be considered advantageous as it provided
the opportunity to collect more relevant and informative
data with respect to symptomatology, diagnosis, treatment
and post-treatment outcomes.
In summary, we provide a contemporary patient
perspective of several aspects of VVC and RVVC that
while largely confirm historical reports, also include
some new insights. Taking into account the overall simi-
larity to historical reports, it bears noting that there has
not been any substantial reduction in lifetime or annual
prevalence rates of VVC over the past 30+ years despite
a number of new drugs and effective maintenance
Table 4 Cure rates following treatment
p-valueb
Physician-treated Relief 84.4% (141)a p < 0.0001
No relief 15.6% (26)
Self-medicated Relief 57.4% (74) NSc
No relief 42.6% (55)
Post-treatment outcome Cure 46.8% (94) NSc
Recurrence 53.2% (107)
RVVCd maintenance regimens Constant/as needed antifungal medication – relief 71.1% (74) p < 0.0001
Constant antifungal medication – no relief 19.2% (20)
Avoiding known risk factors without medication 9.6% (10)
aValues in parentheses indicate the number of respondents who selected each response choice
bData were analyzed by Fisher’s exact test for binomial distribution
cNS, not significant
dRVVC, recurrent vulvovaginal candidiasis defined as 4 or more acute episodes in a 12-month period
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therapy for RVVC. In fact, a study by Denning, et al.
predicts an upward trend in RVVC cases by 2030 [7].
This is also despite a plethora of data regarding the
pathogenesis of disease and potential immunotherapeu-
tic strategies. Hence, continued research is still needed
to impact the incidence of VVC/RVVC. On the positive
side, the fact that VVC and RVVC appear to manifest a
similar, if not identical, clinical pathology suggests that
any diagnostic or immunotherapeutic advances will
benefit either condition. Though we recognize the limi-
tations of this study and selection bias of the respon-
dents, these data represent a current set of patient
trends in several areas that can serve as a useful resource
in future research/publications involving VVC/RVVC.
Conclusions
A contemporary survey of women with a history of VVC
and RVVC provides current trends in prevalence rates,
ranking of disease symptomatology, diagnostic/manage-
ment parameters, and post-treatment outcomes. These
current patient perspectives closely reflect previously
documented estimates and validate historical reports.
Additional file
Additional file 1: Participants’ responses to the questionnaire. The
participants (n = 284) were presented with the survey questionnaire
items (Q) regarding previous history of VVC (Q1), lifetime/annual
frequencies of VVC episodes (Q2-Q3), vulvovaginal signs and symptoms
(Q4), known causes (Q5), choice of clinical interventions for diagnoses
and treatment regimens (Q6), post-treatment outcomes (Q7-Q10) and
participant demographics (Q11-Q13). A set of 2 to 12 answer choices was
included per question. All answer(s) selected by each respondent are indicated
(Sheet 1. Raw data). Respondents selecting other as an answer choice in Q5-
Q6 provided their specified responses as listed in the corresponding
spreadsheets (Sheets 2–3. Q5 others and Q6 others). (XLSX 34 kb)
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